The pandemic’s disruption galvanised the biopharma industry into unprecedented action, demonstrating what’s possible when the global scientific community collaborates in exceptional ways an
In this latest podcast, pharmaphorum spoke to Andrew Meade, life sciences lead UK and Ireland at Accenture, about the trends that emerged in this year’s Q1 results season.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh